SCHEMBL2651867

SCHEMBL2651867

O=C(O)c1cccc(CS)c1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 8/20 0.56
DCLRE1B Q9H816 3/20 0.47
DCLRE1A Q6PJP8 1/20 0.47
HMGB1 P09429 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPT P10636 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
CLCN2 P51788 1/20 0.41
AKR1C3 P42330 1/20 0.41
TSHR P16473 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23708 0.83 FOLH1 (0.50) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL29367715 0.83 FOLH1 (0.50) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL31090800 0.83 FOLH1 (0.50) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL22912 0.83 FOLH1 (0.59) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL5553275 0.82 FOLH1 (0.49) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL605775 0.82 FOLH1 (0.49) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL8482542 0.82 FOLH1 (0.49) FOLH1HMGB1ALDH1A1ALOX15CLCN2
SCHEMBL123735 0.82 CLCN2 (0.54) FOLH1HMGB1ALDH1A1ALOX15CLCN2
Benzene SCHEMBL1931924 0.81 FOLH1 (0.70) FOLH1DCLRE1BDCLRE1AHMGB1ALDH1A1
SCHEMBL2356669 0.81 FOLH1 (0.70) FOLH1DCLRE1BDCLRE1AHMGB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349856-B1 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 EP disclosed
EP-1349856-A2 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-10-08 EP disclosed
US-6482951-B2 ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020082260-A1 Isoindolin-1-one glucokinase activators GUERTIN KEVIN RICHARD (US) 2002-06-27 US disclosed
WO-2002048106-A2 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA-ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082260-A1 Isoindolin-1-one glucokinase activators GCKR, GCK, PGK2 FOLH1 2255/4885DCLRE1B 4107/4885DCLRE1A 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.